Prescription for Gains!
Updated
Recursion Pharmaceuticals is building strong bullish momentum, with a gap forming around the $6.00 level. A breakout above the $8.16 resistance would confirm further upside, targeting the $9.99 weekly resistance. This setup provides an attractive risk-to-reward ratio, with downside managed through a stop-loss at $5.49.
In the longer term, RXRX could extend its bullish run to $15.72, supported by the company’s innovative approach to drug discovery using AI and machine learning. As Recursion leverages technology to streamline the development of new therapies, it has positioned itself as a leader in biotech innovation. The increased adoption of AI in healthcare and RXRX’s strategic partnerships further support its potential for strong revenue growth and long-term value.
With both technical momentum and a compelling growth narrative in biotech, RXRX is well-positioned to reach $9.99 in the near term, with an eye on $15.72 as a longer-term target.
RXRX
In the longer term, RXRX could extend its bullish run to $15.72, supported by the company’s innovative approach to drug discovery using AI and machine learning. As Recursion leverages technology to streamline the development of new therapies, it has positioned itself as a leader in biotech innovation. The increased adoption of AI in healthcare and RXRX’s strategic partnerships further support its potential for strong revenue growth and long-term value.
With both technical momentum and a compelling growth narrative in biotech, RXRX is well-positioned to reach $9.99 in the near term, with an eye on $15.72 as a longer-term target.
RXRX Trade active
Taking some profits here. 
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.